Dataset Information

Ajmaline blocks I_Na and I_Kr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters.

ABSTRACT: The class Ia anti-arrhythmic drug ajmaline is used clinically to unmask latent type I ECG in Brugada syndrome (BrS) patients, although its mode of action is poorly characterised. Our aims were to identify ajmaline's mode of action in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs), and establish a simple BrS hiPSC platform to test whether differences in ajmaline response could be determined between BrS patients and controls. Control hiPSCs were differentiated into spontaneously contracting cardiac clusters. It was found using multi electrode array (MEA) that ajmaline treatment significantly lengthened cluster activation-recovery interval. Patch clamping of single CMs isolated from clusters revealed that ajmaline can block both I_Na and I_Kr. Fol

SUBMITTER: Miller DC

PROVIDER: S-EPMC5727153 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Ajmaline blocks I_Na and I_Kr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Ajmaline blocks INa and IKr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Ajmaline blocks I_Na and I_Kr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters.